Back to User profile » Dr Rickard Sandin
Papers published by Dr Rickard Sandin:
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P
ClinicoEconomics and Outcomes Research 2025, 17:289-302
Published Date: 8 April 2025
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
Pluard TJ, Sandin R, Parikh RC, Ward MA, Stansfield L, Nham T, Esterberg E, Cha-Silva AS, Shah B
ClinicoEconomics and Outcomes Research 2025, 17:247-264
Published Date: 26 March 2025
Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis
Redig J, Dalén J, Harmenberg U, Lindskog M, Ljungberg B, Lundstam S, Sandin R, Wahlgren T, Åkerborg Ö, Jakobsson M
Cancer Management and Research 2019, 11:1289-1297
Published Date: 8 February 2019
Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study
Beisland C, Johannesen TB, Klepp O, Axcrona U, Torgersen KM, Kowalski J, Solli O, Sandin R, Oldenburg J
OncoTargets and Therapy 2017, 10:371-385
Published Date: 16 January 2017
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C
OncoTargets and Therapy 2012, 5:287-296
Published Date: 23 October 2012